LPS-induced inflammatory response after therapy of aggressive periodontitis

J Dent Res. 2013 Aug;92(8):702-8. doi: 10.1177/0022034513495242. Epub 2013 Jun 20.

Abstract

We have reported a lipopolysaccharide (LPS)-induced hyper-inflammatory response in localized aggressive periodontitis (LAP). It is unknown whether treatment is able to modulate this LPS responsiveness. Fifty-nine individuals with LAP were treated by mechanical debridement and systemic antibiotics. Clinical parameters and cyto/chemokine responsiveness of whole blood stimulated with Porphyromonas gingivalis or Escherichia coli LPS were monitored at baseline and 3, 6, and 12 months post-treatment. Overall, clinical parameters were improved following treatment. Additionally, P. gingivalis LPS induction of eotaxin, IFNγ, IL10, IL12p40, IL1β, IL6, IP10, MCP1, MIP1α, GM-CSF, and TNFα was significantly decreased (p < .05). Similarly, induction of eotaxin, INFγ, IL10, IL12p40, GM-CSF, and TNFα by E. coli LPS was also reduced post-treatment. These reductions correlated with decreases in clinical parameters. Importantly, these reductions in LPS responsiveness were most robust at 3 months, and some lost significance at 6 to 12 months post-treatment. In conclusion, LPS-induced hyper-inflammatory response in LAP can be partially modulated by periodontal therapy. Conversely, rebound in the hyper-responsiveness of some mediators, in the presence of improved clinical parameters, suggests that this phenotype could be partially influenced by a genetic trait and play a role in future disease recurrence (ClinicalTrials.gov, NCT01330719).

Keywords: Escherichia coli; Porphyromonas gingivalis; TLR; chemokines; cytokines; immunity; inflammation.

Publication types

  • Clinical Trial
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adolescent
  • Aggressive Periodontitis / immunology
  • Aggressive Periodontitis / therapy*
  • Amoxicillin / therapeutic use
  • Anti-Bacterial Agents / therapeutic use
  • Chemokine CCL2 / analysis
  • Chemokine CCL3 / analysis
  • Chemokine CXCL10 / analysis
  • Chemokines, CC / analysis
  • Child
  • Child, Preschool
  • Escherichia coli / immunology
  • Female
  • Follow-Up Studies
  • Granulocyte-Macrophage Colony-Stimulating Factor / analysis
  • Humans
  • Inflammation Mediators / pharmacology*
  • Interferon-gamma / analysis
  • Interleukin-10 / analysis
  • Interleukin-12 Subunit p40 / analysis
  • Interleukin-1beta / analysis
  • Interleukin-6 / analysis
  • Lipopolysaccharides / pharmacology*
  • Male
  • Metronidazole / therapeutic use
  • Periodontal Attachment Loss / immunology
  • Periodontal Attachment Loss / therapy
  • Periodontal Debridement / methods
  • Periodontal Pocket / immunology
  • Periodontal Pocket / therapy
  • Porphyromonas gingivalis / immunology
  • Tumor Necrosis Factor-alpha / analysis
  • Young Adult

Substances

  • Anti-Bacterial Agents
  • CCL2 protein, human
  • CXCL10 protein, human
  • Chemokine CCL2
  • Chemokine CCL3
  • Chemokine CXCL10
  • Chemokines, CC
  • Inflammation Mediators
  • Interleukin-12 Subunit p40
  • Interleukin-1beta
  • Interleukin-6
  • Lipopolysaccharides
  • Tumor Necrosis Factor-alpha
  • Interleukin-10
  • Metronidazole
  • Amoxicillin
  • Interferon-gamma
  • Granulocyte-Macrophage Colony-Stimulating Factor

Associated data

  • ClinicalTrials.gov/NCT01330719